Immunocore (IMCR) Competitors $32.35 -0.30 (-0.92%) As of 10:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMCR vs. LEGN, RNA, AXSM, ABVX, NUVL, MRUS, CRSP, TGTX, CYTK, and AAPGShould you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Legend Biotech (LEGN), Avidity Biosciences (RNA), Axsome Therapeutics (AXSM), Abivax (ABVX), Nuvalent (NUVL), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), Cytokinetics (CYTK), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Immunocore vs. Its Competitors Legend Biotech Avidity Biosciences Axsome Therapeutics Abivax Nuvalent Merus CRISPR Therapeutics TG Therapeutics Cytokinetics Ascentage Pharma Group International Immunocore (NASDAQ:IMCR) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends. Which has preferable earnings & valuation, IMCR or LEGN? Immunocore has higher earnings, but lower revenue than Legend Biotech. Immunocore is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunocore$310.20M5.26-$51.09M-$0.40-80.88Legend Biotech$627.24M10.11-$177.03M-$0.88-39.23 Do insiders and institutionals hold more shares of IMCR or LEGN? 84.5% of Immunocore shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 10.4% of Immunocore shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is IMCR or LEGN more profitable? Immunocore has a net margin of -5.70% compared to Legend Biotech's net margin of -40.83%. Immunocore's return on equity of -5.40% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Immunocore-5.70% -5.40% -1.93% Legend Biotech -40.83%-32.00%-20.07% Does the media refer more to IMCR or LEGN? In the previous week, Legend Biotech had 12 more articles in the media than Immunocore. MarketBeat recorded 17 mentions for Legend Biotech and 5 mentions for Immunocore. Legend Biotech's average media sentiment score of 1.19 beat Immunocore's score of 1.03 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate IMCR or LEGN? Immunocore currently has a consensus target price of $56.89, suggesting a potential upside of 75.85%. Legend Biotech has a consensus target price of $74.22, suggesting a potential upside of 114.99%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Legend Biotech is more favorable than Immunocore.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunocore 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.55Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 Which has more volatility and risk, IMCR or LEGN? Immunocore has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. SummaryImmunocore and Legend Biotech tied by winning 8 of the 16 factors compared between the two stocks. Get Immunocore News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCR vs. The Competition Export to ExcelMetricImmunocoreMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.64B$3.09B$5.76B$9.78BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-81.2821.1930.8026.45Price / Sales5.26396.45466.65121.64Price / CashN/A44.4437.7659.36Price / Book4.208.1410.216.69Net Income-$51.09M-$54.08M$3.26B$265.42M7 Day Performance-0.98%3.16%3.14%3.41%1 Month Performance-4.68%4.33%4.36%1.09%1 Year Performance-10.49%19.24%45.22%23.47% Immunocore Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCRImmunocore1.5771 of 5 stars$32.35-0.9%$56.89+75.9%-9.7%$1.64B$310.20M-81.28320Positive NewsAnalyst ForecastLEGNLegend Biotech3.8986 of 5 stars$34.60-2.7%$73.00+111.0%-39.1%$6.53B$627.24M-39.322,609News CoveragePositive NewsAnalyst ForecastRNAAvidity Biosciences2.9816 of 5 stars$45.27-2.3%$67.00+48.0%+9.4%$5.96B$10.90M-12.72190Positive NewsAXSMAxsome Therapeutics4.7897 of 5 stars$116.31-1.9%$178.00+53.0%+37.0%$5.91B$385.69M-22.94380News CoveragePositive NewsInsider TradeABVXAbivax2.7304 of 5 stars$77.46+0.2%$92.33+19.2%+564.1%$5.84BN/A0.0061News CoveragePositive NewsAnalyst RevisionNUVLNuvalent3.4396 of 5 stars$74.05-2.7%$118.91+60.6%-9.7%$5.49BN/A-15.1140News CoveragePositive NewsMRUSMerus2.318 of 5 stars$65.74-2.6%$88.64+34.8%+26.9%$5.10B$36.13M-11.9537News CoveragePositive NewsAnalyst ForecastCRSPCRISPR Therapeutics3.529 of 5 stars$54.13-0.3%$71.60+32.3%+11.0%$4.94B$37.31M-9.97460Positive NewsAnalyst UpgradeTGTXTG Therapeutics4.4135 of 5 stars$28.53-3.1%$46.25+62.1%+23.6%$4.67B$329M77.11290Positive NewsCYTKCytokinetics3.7506 of 5 stars$37.01-3.5%$71.58+93.4%-32.3%$4.59B$18.47M-7.26250News CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$43.48-9.2%N/AN/A$4.45B$134.35M0.00600High Trading Volume Related Companies and Tools Related Companies LEGN Competitors RNA Competitors AXSM Competitors ABVX Competitors NUVL Competitors MRUS Competitors CRSP Competitors TGTX Competitors CYTK Competitors AAPG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMCR) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access